Nisa Investment Advisors LLC Acquires 25,063 Shares of Iqvia Holdings Inc (IQV)

Nisa Investment Advisors LLC increased its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 118.0% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 46,302 shares of the medical research company’s stock after purchasing an additional 25,063 shares during the period. Nisa Investment Advisors LLC’s holdings in Iqvia were worth $6,661,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Bank of New York Mellon Corp boosted its stake in shares of Iqvia by 0.8% during the third quarter. Bank of New York Mellon Corp now owns 1,203,632 shares of the medical research company’s stock valued at $156,159,000 after purchasing an additional 9,522 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Iqvia by 2,582.7% during the third quarter. Renaissance Technologies LLC now owns 147,547 shares of the medical research company’s stock valued at $19,143,000 after purchasing an additional 142,047 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Iqvia by 116.2% during the third quarter. LPL Financial LLC now owns 19,827 shares of the medical research company’s stock valued at $2,572,000 after purchasing an additional 10,655 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Iqvia by 9.8% during the third quarter. The Manufacturers Life Insurance Company now owns 165,042 shares of the medical research company’s stock valued at $21,412,000 after purchasing an additional 14,668 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of Iqvia by 13.7% during the third quarter. Pacer Advisors Inc. now owns 9,320 shares of the medical research company’s stock valued at $1,209,000 after purchasing an additional 1,120 shares in the last quarter. Hedge funds and other institutional investors own 91.01% of the company’s stock.

A number of research firms have recently issued reports on IQV. Wolfe Research began coverage on shares of Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating on the stock. Barclays increased their price objective on shares of Iqvia from $160.00 to $167.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. Argus increased their price objective on shares of Iqvia from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, February 25th. They noted that the move was a valuation call. Wells Fargo & Co increased their price objective on shares of Iqvia from $140.00 to $160.00 and gave the company an “outperform” rating in a research note on Tuesday, February 19th. Finally, UBS Group set a $170.00 target price on shares of Iqvia and gave the company a “buy” rating in a research note on Friday, February 15th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. Iqvia presently has a consensus rating of “Buy” and an average price target of $146.88.

In other Iqvia news, insider W Richard Staub sold 27,025 shares of the firm’s stock in a transaction on Wednesday, February 20th. The shares were sold at an average price of $140.54, for a total value of $3,798,093.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Evanisko sold 1,193 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,172,538 shares of company stock valued at $587,465,163. Corporate insiders own 6.00% of the company’s stock.

Shares of IQV opened at $133.01 on Friday. The company has a market capitalization of $26.31 billion, a price-to-earnings ratio of 25.98, a PEG ratio of 1.62 and a beta of 0.85. Iqvia Holdings Inc has a twelve month low of $91.57 and a twelve month high of $146.10. The company has a debt-to-equity ratio of 1.57, a current ratio of 1.10 and a quick ratio of 1.10.

Iqvia (NYSE:IQV) last announced its earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.47 by $0.03. The company had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. Iqvia’s revenue was up 6.6% compared to the same quarter last year. During the same period last year, the firm earned $1.40 earnings per share. On average, equities analysts predict that Iqvia Holdings Inc will post 5.87 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/nisa-investment-advisors-llc-acquires-25063-shares-of-iqvia-holdings-inc-iqv.html.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: What are retained earnings?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.